NASDAQ:BOLD Boundless Bio (BOLD) Stock Price, News & Analysis $2.70 -0.18 (-6.25%) Closing price 04:00 PM EasternExtended Trading$2.72 +0.01 (+0.56%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnership About Boundless Bio Stock (NASDAQ:BOLD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Boundless Bio alerts:Sign Up Key Stats Today's Range$2.69▼$2.8950-Day Range$2.44▼$3.0052-Week Range$0.96▼$3.16Volume170,119 shsAverage Volume88,570 shsMarket Capitalization$61.43 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Boundless Bio, Inc. is a clinical-stage biotechnology company focused on developing targeted medicines for patients with oncogene-amplified cancers. The company’s research centers on extrachromosomal DNA (ecDNA), circular DNA structures found outside chromosomes that can contain multiple copies of cancer-driving genes and contribute to tumor growth, treatment resistance and disease progression. Boundless Bio uses its proprietary Spyglass platform to identify and characterize ecDNA and discover potential drug targets. Its pipeline includes ecDNA-directed small-molecule therapies designed to selectively disrupt the biology of tumors that depend on oncogene amplification. The company is advancing these programs through preclinical research and clinical development in solid tumors. Founded in 2018 and headquartered in San Diego, California, Boundless Bio serves the global oncology research and biopharmaceutical markets through its drug-discovery and development efforts. The company became publicly traded on the Nasdaq under the symbol BOLD in 2024.AI Generated. May Contain Errors. Read More Boundless Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks16th Percentile Overall ScoreBOLD MarketRank™: Boundless Bio scored higher than 16% of companies evaluated by MarketBeat, and ranked 832nd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingBoundless Bio has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 2 sell ratings.Amount of Analyst CoverageBoundless Bio has only been the subject of 1 research reports in the past 90 days.Read more about Boundless Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Boundless Bio is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Boundless Bio is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBoundless Bio has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.65% of the float of Boundless Bio has been sold short.Short Interest Ratio / Days to CoverBoundless Bio has a short interest ratio ("days to cover") of 7.04.Change versus previous monthShort interest in Boundless Bio has recently increased by 17.96%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBoundless Bio does not currently pay a dividend.Dividend GrowthBoundless Bio does not have a long track record of dividend growth. News and Social MediaN/ANews SentimentN/A Company Ownership3.6 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $510,654.00 in company stock, which represents 0.8313% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Boundless Bio insiders have bought 381.00% more of their company's stock than they have sold. Specifically, they have bought $644,685.00 in company stock and sold $134,031.00 in company stock.Percentage Held by Insiders23.10% of the stock of Boundless Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsBoundless Bio has minimal institutional ownership at this time.Read more about Boundless Bio's insider trading history. Receive BOLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Boundless Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BOLD Stock News HeadlinesSerapha Bio Appoints Kenneth T. Mills as Chief Executive Officer and Names Senior Leadership Team to Advance Potential Best-in-Class in vivo Base Editing Program for Alpha-1 Antitrypsin DeficiencySeptember 15, 2026 | globenewswire.comCallio Therapeutics Appoints Zachary Hornby as Chief Executive OfficerSeptember 9, 2026 | globenewswire.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 23 at 1:00 AM | Stansberry Research (Ad)Halper Sadeh LLC is Investigating Whether BOLD and NDRA are Obtaining Fair Deals for their ShareholdersJuly 2, 2026 | globenewswire.comBoundless Bio to merge with Serapha Bio in reverse merger; shares surgeJune 23, 2026 | msn.comBOLD Stock Is Up 90% — Here's What's Behind The Biggest Rally In Company HistoryJune 23, 2026 | finance.yahoo.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD)June 23, 2026 | prnewswire.comBoundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private PlacementJune 23, 2026 | globenewswire.comSee More Headlines BOLD Stock Analysis - Frequently Asked Questions How have BOLD shares performed this year? Boundless Bio's stock was trading at $1.18 at the start of the year. Since then, BOLD stock has increased by 128.8% and is now trading at $2.70. How were Boundless Bio's earnings last quarter? Boundless Bio, Inc. (NASDAQ:BOLD) issued its quarterly earnings results on Friday, August, 7th. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter. When did Boundless Bio IPO? Boundless Bio (BOLD) raised $100 million in an IPO on Thursday, March 28th 2024. The company issued 6,250,000 shares at $15.00-$17.00 per share. Who are Boundless Bio's major shareholders? Top institutional investors of Boundless Bio include ARCH Venture Management LLC (11.84%), ADAR1 Capital Management LLC (8.65%), Wellington Management Group LLP (2.44%) and Stonepine Capital Management LLC (0.68%). Insiders that own company stock include Ra Capital Management, LP and Venture Fund Ix LP Arch. View institutional ownership trends. How do I buy shares of Boundless Bio? Shares of BOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Boundless Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Boundless Bio investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Alphabet (GOOG) and Visa (V). Company Calendar Last Earnings8/07/2026Today9/23/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 BOLD's financial health is in the Green zone, according to TradeSmith. BOLD has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BOLD CIK0001782303 Webwww.boundlessbio.com Phone(858) 766-9912FaxN/AEmployees28Year Founded2018Profitability EPS (Trailing Twelve Months)($2.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$58.20 million Net MarginsN/A Pretax MarginN/A Return on Equity-70.89% Return on Assets-47.37% Debt Debt-to-Equity RatioN/A Current Ratio9.48 Quick Ratio9.48 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.41 per share Price / Book0.61Miscellaneous Outstanding Shares22,750,000Free Float17,493,000Market Cap$61.43 million OptionableNo Data Beta-0.03 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:BOLD) was last updated on 9/23/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Boundless Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Boundless Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
